Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potentially first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves’ disease and thyroid eye disease. By directly binding to TSHR and protecting this receptor from autoantibody attack, YB-101 offers the potential to address both thyroidal and extra-thyroidal manifestations of these diseases without the risk of serious toxicities or immunosuppression.